CSL Behring Makes Annual Start-Up Grants Available to Next Generation of Coagulation Researchers

GENEVA, July 9 /PRNewswire/ --

- Awards Named in Honor of Professor Norbert Heimburger, Pioneer of 
Modern Coagulation Research

CSL Behring, a global leader in the protein biotherapeutics industry,
announced today at the International Society on Thrombosis and Haemostasis
(ISTH) XXIst Congress that it will award five annual grants to support new
research projects in the area of coagulation. The start-up grants of 20,000
euros each ($26,780 U.S.) will be awarded to young medical researchers for
preclinical and/or clinical coagulation projects based on the scientific
merit of their work.

The grant is named in honor of Professor Norbert Heimburger, a pioneer of
modern coagulation therapy and a CSL Behring employee for over three decades.
Among his many achievements was the development of virus-safe plasma products
based on pasteurization. Due to his research efforts, Behring launched the
first effectively virus-inactivated FVIII concentrate in 1981.

"CSL Behring is committed to advancing research that furthers our
understanding of coagulation and improves the treatment of bleeding disorders
such as hemophilia and von Willebrand disease," said Roland Martin, Head of
Research and Development at CSL Behring. "Supporting the next generation of
specialists to medically and scientifically establish themselves is important
to have continued progress in this therapeutic area."

Grant applications must be received by February 1, 2008. They will be
reviewed by a special selection committee of four scientifically renowned
clinicians in the coagulation field: Erik Berntorp, MD, PhD, Malmo University
Hospital, Sweden; Jorge DiPaola, MD, Great Plains Regional Hemophilia
Treatment Center, USA; David Lillicrap, M.D., FRCPC, Queen's University,
Canada; and Johannes Oldenburg, M.D. PhD, University of Bonn, Germany.

For more information regarding the Professor Norbert Heimburger Grant and
specific criteria for applications, please go to
www.cslbehring.com/ProfHeimburgerAward.

About CSL Behring

CSL Behring is a global leader in the plasma protein biotherapeutics
industry. Passionate about saving and improving the quality of patients'
lives, CSL Behring manufactures and markets a range of safe and effective
plasma-derived and recombinant products and related services. The company's
therapies are used in the treatment of rare diseases such as immune
deficiency disorders, hemophilia, von Willebrand disease, other bleeding
disorders and inherited emphysema. Other products are used for the prevention
of hemolytic diseases in the newborn, in cardiac surgery, organ
transplantation and in the treatment of burns. The company also operates one
of the world's largest plasma collection networks, ZLB Plasma. CSL Behring is
a subsidiary of CSL Limited, a biopharmaceutical company with headquarters in
Melbourne, Australia. For more information, visit www.cslbehring.com.

Contact:
    Sheila A. Burke, Director, Communications & Public Relations
    Worldwide Commercial Operations
    CSL Behring
    +1-610-878-4209
    Sheila.Burke@cslbehring.com


    Web site: http://www.cslbehring.com
              http://www.cslbehring.com/ProfHeimburgerAward